Clinical Trials

1,083 enrolled 29 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT02003924 2026-01-27

PROSPER

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT03338790 2026-01-27

CheckMate 9KD

292 enrolled 21 charts

Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

455 enrolled 18 charts

Prostatic Neoplasms

NCT06072196 2025-12-31

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

3,017 enrolled 5 charts

Prostatic Neoplasms

NCT05457257 2025-12-19

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

43 enrolled 16 charts

Metastatic Castration-resistant Prostate Cancer

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT03480646 2025-10-29

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Completed

175 enrolled 23 charts

Tumor-Agnostic

Neoplasms

NCT02294461 2025-10-24

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

395 enrolled 25 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02677896 2025-10-24

ARCHES

1,150 enrolled 23 charts 2 FDA

Metastatic Hormone Sensitive Prostate Cancer

NCT03939689 2025-10-14

ARROW

120 enrolled 21 charts

Prostatic Neoplasms

NCT04934722 2025-10-01

KEYNOTE-991

186 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02007512 2025-09-02

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

247 enrolled 27 charts

Breast

Breast Neoplasms

NCT02975934 2025-07-25

TRITON3

405 enrolled 34 charts 3 FDA

Metastatic Castration Resistant Prostate Cancer

NCT03834493 2025-07-18

KEYNOTE-641

1,244 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02204072 2025-07-15

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Phase 1 Completed

120 enrolled 28 charts

Prostatic Neoplasms, Castration-Resistant

NCT02319837 2025-07-08

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

1,068 enrolled 20 charts 2 FDA

Prostatic Neoplasms

NCT06151418 2025-06-04

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

2,313 enrolled 5 charts

Prostatic Neoplasms

NCT03834519 2025-05-18

KEYLYNK-010

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02288247 2025-04-08

PRESIDE

688 enrolled 13 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT03641560 2025-04-08

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

52 enrolled 10 charts

Metastatic Castration Resistant Prostate Cancer

NCT02091960 2025-04-04

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

103 enrolled 17 charts

Breast

Breast Neoplasms

NCT01889238 2024-12-13

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

118 enrolled 23 charts

Breast

Breast Neoplasms

NCT01650194 2024-12-10

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

60 enrolled 24 charts

Tumor-Agnostic

Neoplasms

NCT02918968 2024-12-09

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

206 enrolled 16 charts

Prostatic Neoplasms

NCT01288911 2024-12-06

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

375 enrolled 24 charts

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT01534052 2024-12-06

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

52 enrolled 16 charts

Prostatic Neoplasms

NCT01977651 2024-12-06

UPWARD

424 enrolled 10 charts

Seizures

NCT02116582 2024-12-06

A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer

215 enrolled 11 charts

Metastatic Castration-Resistant Prostate Cancer

NCT02799745 2024-12-06

ENACT

227 enrolled 24 charts

Prostatic Neoplasms

NCT05520138 2024-09-27

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

5,506 enrolled 11 charts

Prostatic Neoplasms, Castration-Resistant

NCT03016312 2024-08-09

IMbassador250

759 enrolled 22 charts

BreastDermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Prostatic Neoplasms, Castration-Resistant

NCT03685591 2024-06-26

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

49 enrolled 33 charts

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

387 enrolled 16 charts 3 FDA

Metastatic Castration-resistant Prostate Cancer

NCT01995513 2023-09-18

PLATO

509 enrolled 18 charts

Prostatic Neoplasms

NCT04157088 2023-08-04

DaroAcT

Phase 2 Terminated

30 enrolled 25 charts

Prostatic Neoplasms, Castration-Resistant

NCT04179396 2023-06-29

RAMP

Phase 1 Completed

8 enrolled 8 charts

Metastatic Castration Resistant Prostate Cancer

NCT03150056 2022-08-10

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

Phase 1 Terminated

73 enrolled 34 charts

Other solid neoplasm

Solid Tumours

NCT02485691 2022-05-27

CARD

255 enrolled 21 charts

Prostate Cancer Metastatic

NCT02711956 2021-11-30

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Completed

75 enrolled 31 charts

Prostatic Neoplasms

NCT04052204 2021-10-14

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

3 enrolled 12 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02407054 2021-05-11

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

142 enrolled 16 charts

Prostate Cancer Metastatic

NCT02607228 2020-12-08

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

Phase 1/2 Terminated

31 enrolled 22 charts